loading
Schlusskurs vom Vortag:
$1.89
Offen:
$1.87
24-Stunden-Volumen:
1.55M
Relative Volume:
1.16
Marktkapitalisierung:
$202.15M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-1.6652
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+22.70%
1M Leistung:
+25.17%
6M Leistung:
-52.42%
1J Leistung:
-74.76%
1-Tages-Spanne:
Value
$1.72
$1.93
1-Wochen-Bereich:
Value
$1.40
$3.00
52-Wochen-Spanne:
Value
$1.03
$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name
Firmenname
Tango Therapeutics Inc
Name
Telefon
(857) 320-4900
Name
Adresse
201 BROOKLINE AVENUE, BOSTON
Name
Mitarbeiter
155
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
TNGX's Discussions on Twitter

Vergleichen Sie TNGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TNGX
Tango Therapeutics Inc
1.865 164.76M 42.51M -116.49M -120.82M -1.12
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-17 Eingeleitet Jefferies Buy
2024-04-04 Eingeleitet Cantor Fitzgerald Overweight
2024-02-12 Eingeleitet Piper Sandler Overweight
2023-12-08 Eingeleitet B. Riley Securities Buy
2022-10-20 Hochstufung H.C. Wainwright Neutral → Buy
2021-09-20 Eingeleitet SVB Leerink Outperform
Alle ansehen

Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten

pulisher
May 22, 2025

Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan

May 21, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World

May 18, 2025
pulisher
May 16, 2025

Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World

May 16, 2025
pulisher
May 15, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 15, 2025
pulisher
May 15, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 14, 2025
pulisher
May 13, 2025

Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks

May 13, 2025
pulisher
May 12, 2025

Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus

May 12, 2025
pulisher
May 12, 2025

TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 12, 2025
pulisher
May 10, 2025

Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World

May 09, 2025
pulisher
May 08, 2025

21,500 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Renaissance Technologies LLC - Defense World

May 08, 2025
pulisher
May 06, 2025

JPMorgan Chase & Co. Has $97,000 Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 06, 2025
pulisher
May 05, 2025

Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance

May 05, 2025
pulisher
May 05, 2025

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study - Barchart.com

May 05, 2025
pulisher
May 01, 2025

There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News

May 01, 2025
pulisher
May 01, 2025

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire

May 01, 2025
pulisher
Apr 30, 2025

Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com

Apr 30, 2025
pulisher
Apr 30, 2025

Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com

Apr 30, 2025
pulisher
Apr 29, 2025

Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX

Apr 29, 2025
pulisher
Apr 28, 2025

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

Apr 28, 2025
pulisher
Apr 27, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World

Apr 27, 2025
pulisher
Apr 26, 2025

Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel

Apr 26, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 18, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World

Apr 17, 2025
pulisher
Apr 17, 2025

Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Tango Bypasses IPO Route With SPAC Merger - insights.citeline.com

Apr 16, 2025
pulisher
Apr 16, 2025

What is HC Wainwright’s Estimate for TNGX Q1 Earnings? - Defense World

Apr 16, 2025
pulisher
Apr 15, 2025

Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st

Apr 14, 2025

Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):